These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

938 related articles for article (PubMed ID: 19505804)

  • 1. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
    Tré-Hardy M; Traore H; El Manssouri N; Vanderbist F; Vaneechoutte M; Devleeschouwer MJ
    Int J Antimicrob Agents; 2009 Oct; 34(4):370-4. PubMed ID: 19505804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model.
    Tré-Hardy M; Macé C; El Manssouri N; Vanderbist F; Traore H; Devleeschouwer MJ
    Int J Antimicrob Agents; 2009 Jan; 33(1):40-5. PubMed ID: 18801647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures.
    Tré-Hardy M; Vanderbist F; Traore H; Devleeschouwer MJ
    Int J Antimicrob Agents; 2008 Apr; 31(4):329-36. PubMed ID: 18280117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.
    Hill D; Rose B; Pajkos A; Robinson M; Bye P; Bell S; Elkins M; Thompson B; Macleod C; Aaron SD; Harbour C
    J Clin Microbiol; 2005 Oct; 43(10):5085-90. PubMed ID: 16207967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bismuth-thiol incorporation enhances biological activities of liposomal tobramycin against bacterial biofilm and quorum sensing molecules production by Pseudomonas aeruginosa.
    Halwani M; Hebert S; Suntres ZE; Lafrenie RM; Azghani AO; Omri A
    Int J Pharm; 2009 May; 373(1-2):141-6. PubMed ID: 19429299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
    Burns JL; Van Dalfsen JM; Shawar RM; Otto KL; Garber RL; Quan JM; Montgomery AB; Albers GM; Ramsey BW; Smith AL
    J Infect Dis; 1999 May; 179(5):1190-6. PubMed ID: 10191222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Investigation of biofilm formation and relationship with genotype and antibiotic susceptibility of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis].
    Coban AY; Ciftci A; Onuk EE; Erturan Z; Tanriverdi Cayci Y; Durupinar B
    Mikrobiyol Bul; 2009 Oct; 43(4):563-73. PubMed ID: 20084909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
    Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G
    J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model.
    Tré-Hardy M; Nagant C; El Manssouri N; Vanderbist F; Traore H; Vaneechoutte M; Dehaye JP
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4409-15. PubMed ID: 20696878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro approach to study the synergistic effects of tobramycin and clarithromycin against Pseudomonas aeruginosa biofilms using prokaryotic or eukaryotic culture media.
    Thellin O; Zorzi W; Jolois O; Elmoualij B; Duysens G; Cahay B; Streel B; Charif M; Bastin R; Heinen E; Quatresooz P
    Int J Antimicrob Agents; 2015 Jul; 46(1):33-8. PubMed ID: 25963337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of gentamicin and tobramycin on binary biofilm formation by co-cultures of Burkholderia cepacia and Pseudomonas aeruginosa.
    Al-Bakri AG; Gilbert P; Allison DG
    J Basic Microbiol; 2005; 45(5):392-6. PubMed ID: 16187262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment.
    MacLeod DL; Nelson LE; Shawar RM; Lin BB; Lockwood LG; Dirk JE; Miller GH; Burns JL; Garber RL
    J Infect Dis; 2000 Mar; 181(3):1180-4. PubMed ID: 10720551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
    Moriarty TF; McElnay JC; Elborn JS; Tunney MM
    Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anaerobic culture conditions favor biofilm-like phenotypes in Pseudomonas aeruginosa isolates from patients with cystic fibrosis.
    O'May CY; Reid DW; Kirov SM
    FEMS Immunol Med Microbiol; 2006 Dec; 48(3):373-80. PubMed ID: 17052266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
    McCaughey G; McKevitt M; Elborn JS; Tunney MM
    J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In vitro bactericidal activity of tobramycin and amikacin alone or in combination against Pseudomonas aeruginosa isolated from patients with cystic fibrosis].
    Bertrou A; Marty N; Henry S; Agueda L; Chabanon G
    Pathol Biol (Paris); 1990 May; 38(5):366-75. PubMed ID: 2114606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased bacterial adherence and biomass in Pseudomonas aeruginosa bacteria exposed to clarithromycin.
    Garey KW; Vo QP; Lewis RE; Saengcharoen W; LaRocco MT; Tam VH
    Diagn Microbiol Infect Dis; 2009 Jan; 63(1):81-6. PubMed ID: 18990530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections.
    Meers P; Neville M; Malinin V; Scotto AW; Sardaryan G; Kurumunda R; Mackinson C; James G; Fisher S; Perkins WR
    J Antimicrob Chemother; 2008 Apr; 61(4):859-68. PubMed ID: 18305202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
    Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
    Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro interactions of tobramycin with various nonantibiotics against Pseudomonas aeruginosa and Burkholderia cenocepacia.
    Treerat P; Widmer F; Middleton PG; Iredell J; George AM
    FEMS Microbiol Lett; 2008 Aug; 285(1):40-50. PubMed ID: 18513356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.